Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All vitamin B9 studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin B9Vitamin B9 (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019-nCoVMpro), Molecular Docking and SAR Study

Serseg et al., Current Computer-Aided Drug Design, doi:10.2174/1573409916666200422075440
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Silico study identifying folic acid, hispidin, and lepidine E as potential SARS-CoV-2 Mpro inhibitors.
14 preclinical studies support the efficacy of vitamin B9 for COVID-19:
Vitamin B9 has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function12-14. Vitamin B9 inhibits SARS-CoV-2 In Silico3-11, reduces spike protein binding ability11, binds with the spike protein receptor binding domain for alpha and omicron variants2, inhibits the SARS-CoV-2 nucleocapsid protein3, inhibits 3CLpro and PLpro in enzymatic assays2, significantly reduces infection for alpha and omicron SARS-CoV-2 pseudoviruses2, and inhibits ACE2 expression and SARS-CoV-2 infection in a mouse model11.
Serseg et al., 15 Jul 2021, peer-reviewed, 3 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperVitamin B9All
{ 'indexed': {'date-parts': [[2023, 3, 27]], 'date-time': '2023-03-27T01:48:51Z', 'timestamp': 1679881731822}, 'reference-count': 0, 'publisher': 'Bentham Science Publishers Ltd.', 'issue': '3', 'content-domain': {'domain': ['eurekaselect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 7, 15]]}, 'abstract': '<jats:sec>\n' '<jats:title>Background:</jats:title>\n' '<jats:p>2019-nCoVis, a novel coronavirus was isolated and identified in 2019 in\n' 'the city of Wuhan, China. On February 17, 2020 and according to the World Health ' 'Organization,\n' '71, 429 confirmed cases worldwide were identified, among them 2162 new cases were recorded ' 'in\n' 'the last 24 hours. One month later, the confirmed cases jumped to 179111, with 11525 new ' 'cases in\n' 'the last 24 hours, with 7426 total deaths. No drug or vaccine is present at the moment for ' 'human\n' 'and animal coronavirus.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Methods:</jats:title>\n' '<jats:p>The inhibition of 3CL hydrolase enzyme provides a promising therapeutic principle ' 'for\n' 'developing treatments against CoViD-19. The 3CLpro (Mpro) is known for involving in ' 'counteracting\n' 'the host innate immune response.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Results:</jats:title>\n' '<jats:p>This work presents the inhibitory effect of some natural compounds against 3CL ' 'hydrolase\n' 'enzyme, and explains the main interactions in inhibitor-enzyme complex. Molecular docking ' 'study\n' 'was carried out using Autodock Vina. By screening several molecules, we identified three ' 'candidate\n' 'agents that inhibit the main protease of coronavirus. Hispidin, lepidine E, and folic acid ' 'are\n' 'bound tightly in the enzyme, therefore strong hydrogen bonds have been formed (1.69-1.80Å) ' 'with\n' 'the active site residues.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Conclusion:</jats:title>\n' '<jats:p>This study provides a possible therapeutic strategy for CoViD-19.</jats:p>\n' '</jats:sec>', 'DOI': '10.2174/1573409916666200422075440', 'type': 'journal-article', 'created': {'date-parts': [[2020, 4, 23]], 'date-time': '2020-04-23T03:12:48Z', 'timestamp': 1587611568000}, 'page': '469-479', 'update-policy': 'http://dx.doi.org/10.2174/bsp_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 37, 'title': 'Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of ' '2019-novel Coronavirus Main Protease (2019-nCoVMpro), Molecular Docking and SAR Study', 'prefix': '10.2174', 'volume': '17', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-5197-1024', 'authenticated-orcid': True, 'given': 'Talia', 'family': 'Serseg', 'sequence': 'first', 'affiliation': [ { 'name': 'Laboratoire des Sciences Fondamentales, Faculte des Sciences, ' 'Universite Amar Telidji, Laghouat, Algeria'}]}, { 'ORCID': 'http://orcid.org/0000-0001-9112-6730', 'authenticated-orcid': True, 'given': 'Khedidja', 'family': 'Benarous', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratoire des Sciences Fondamentales, Faculte des Sciences, ' 'Universite Amar Telidji, Laghouat, Algeria'}]}, { 'ORCID': 'http://orcid.org/0000-0003-3947-9867', 'authenticated-orcid': True, 'given': 'Mohamed', 'family': 'Yousfi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratoire des Sciences Fondamentales, Faculte des Sciences, ' 'Universite Amar Telidji, Laghouat, Algeria'}]}], 'member': '965', 'container-title': 'Current Computer-Aided Drug Design', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://eurekaselect.com/article/download/181163', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.eurekaselect.com/181163/article', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://eurekaselect.com/article/download/181163', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 7, 22]], 'date-time': '2021-07-22T14:13:34Z', 'timestamp': 1626963214000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.eurekaselect.com/181163/article'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 7, 15]]}, 'references-count': 0, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2021, 7, 15]]}}, 'alternative-id': ['LiveAll1'], 'URL': 'http://dx.doi.org/10.2174/1573409916666200422075440', 'relation': {}, 'ISSN': ['1573-4099'], 'subject': ['Drug Discovery', 'Molecular Medicine', 'General Medicine'], 'container-title-short': 'CAD', 'published': {'date-parts': [[2021, 7, 15]]}, 'assertion': [ { 'value': 'Peer Reviewed', 'order': 0, 'name': 'review_status', 'label': 'Review Status', 'group': {'name': 'peer_review_details', 'label': 'Peer Review Details'}}, { 'value': 'Single blind', 'order': 1, 'name': 'review_process', 'label': 'Review Process', 'group': {'name': 'peer_review_details', 'label': 'Peer Review Details'}}, { 'value': 'Checked with iThenticate', 'order': 0, 'name': 'screening_status', 'label': 'Screening Status', 'group': {'name': 'plagiarism_screening', 'label': 'Plagiarism Screening'}}, { 'value': '2020-02-25', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-03-19', 'order': 1, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-04-08', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-07-15', 'order': 3, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit